Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03774264 · ClinicalTrials.gov registry record
Treatment Response to Xiaflex for Men With Peyronie's Disease
A clinical trial of Peyronie Disease, sponsored by University of Miami.
- Completed
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT03774264 is a study of Peyronie Disease that has completed, run by University of Miami. The registered enrollment target is 80 participants, above the 41-participant average among 3 other Peyronie Disease trials with a reported enrollment target (95% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03774264, a study of Peyronie Disease, has completed, sponsored by University of Miami.
- COMPLETED
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research study is to develop a database of patients with Peyronie's disease who are treated at the University of Miami. The collected data will help the researchers to better understand Peyronie's disease and its response to therapy.
Conditions Studied
Study Locations (1)
Florida
- Department of Urology, University of Miami - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2018-09-02 |
| Est. Completion | 2021-07-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03774264
The ClinicalTrials.gov registry entry for NCT03774264 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 80 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 41-participant average among 3 other Peyronie Disease trials with a reported enrollment target (95% higher). The listed sponsor is University of Miami, which has 721 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peyronie Disease appearing as the primary indexed condition, and to 0 interventions.
NCT03774264 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03774264 about?
NCT03774264 is a clinical study titled "Treatment Response to Xiaflex for Men With Peyronie's Disease". The purpose of this research study is to develop a database of patients with Peyronie's disease who are treated at the University of Miami. The collected data will help the researchers to better understand Peyronie's disease and its response to therapy.
What is the current status of trial NCT03774264?
This trial is currently completed. The enrollment target is 80 participants. The study started on 2018-09-02. Estimated completion is 2021-07-02.
What conditions does trial NCT03774264 study?
This clinical trial studies the following conditions: Peyronie Disease.
Who is sponsoring clinical trial NCT03774264?
This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03774264 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peyronie Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Concurrent Low Intensity Shockwave Therapy on Collagenase Clostridium Histolyticum for Peyronie's Disease
RECRUITING · NA
-
Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease
RECRUITING · Phase 4
-
Delayed Dose Collagenase Clostridium Histolyticum (CCH) Protocol for Men With Peyronie's Disease
RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.